--- title: "Himalaya Nutravedics India Ltd (1286186) — Share Price, Financials & Analysis" symbol: "1286186" company: "Himalaya Nutravedics India Ltd" canonical: "https://tapetide.com/stocks/1286186" isin: "INE1OTR01013" bse_code: "544943" sector: "Healthcare" industry: "Pharmaceuticals & Biotechnology" market_cap_cr: 100.6 generated_at: "2026-10-13T11:01:22.547Z" --- # Himalaya Nutravedics India Ltd (1286186) Canonical page: https://tapetide.com/stocks/1286186 ## Company - **BSE Code:** 544943 - **ISIN:** INE1OTR01013 - **Sector:** Healthcare - **Industry:** Pharmaceuticals & Biotechnology - **Macro Sector:** Healthcare - **Face Value:** ₹10 - **F&O Eligible:** No ## About Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations.[1] ## Latest Price ## Key Fundamentals Price-based figures as of 2026-10-12T15:30:00+05:30. Observed at 2026-10-13T04:33:30.879381Z. - **Market Cap:** ₹100.6 Cr - **Classification:** SME - **Book Value:** ₹48.69 - **Price to Book:** 2.35 - **Dividend Yield:** 0% - **ROE:** 45.11% - **ROCE:** 47.4% - **Debt to Equity:** 0.31 - **Revenue (yearly):** ₹43.1 Cr - **Net Income:** ₹7.4 Cr - **EBITDA:** ₹8.2 Cr - **52-Week High:** ₹135.1 - **52-Week Low:** ₹111 ## Key Insights ### Strengths - Company has a good return on equity (ROE) track record: 3 Years ROE 59.8% ### Weaknesses - Working capital days have increased from 69.7 days to 105 days ## Growth Rates | Metric | 1Y | 3Y | 5Y | | --- | --- | --- | --- | | cash flow growth | -175.54% | -596.36% | -177.37% | | ebitda margin growth | 32.79% | 190.48% | — | | net income growth | 236.36% | 267% | — | | revenue growth | 105.24% | 176% | — | ## Financial Statements ### Profit & Loss All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | | --- | --- | --- | --- | --- | | Sales | 2.05 | 14.43 | 21 | 43.06 | | Expenses | 1.77 | 13.49 | 18.01 | 34.95 | | Operating Profit | 0.28 | 0.94 | 2.99 | 8.11 | | OPM % | 13.66 | 6.51 | 14.24 | 18.83 | | Other Income | 0 | 0 | 0 | 0.05 | | Interest | 0.02 | 0.18 | 0.32 | 0.35 | | Depreciation | 0.06 | 0.16 | 0.42 | 0.33 | | Profit before tax | 0.2 | 0.6 | 2.25 | 7.48 | | Tax % | 25 | 28.33 | 0.89 | 1.2 | | Net Profit | 0.15 | 0.43 | 2.23 | 7.39 | | EPS in Rs | 1.81 | 5.18 | 5.58 | 11.72 | | Dividend Payout % | 0 | 0 | 0 | 0 | ### Balance Sheet All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | | --- | --- | --- | --- | --- | | Equity Capital | 0.83 | 0.83 | 4 | 6.31 | | Reserves | 0.15 | 0.53 | 2.76 | 10.07 | | Borrowings | 1.32 | 3.24 | 1.76 | 5.13 | | Other Liabilities | 0.93 | 1.49 | 2.3 | 2.91 | | Total Liabilities | 3.23 | 6.09 | 10.82 | 24.42 | | Fixed Assets | 0.58 | 1.5 | 1.29 | 1.03 | | CWIP | 0 | 0 | 0 | 0 | | Investments | 0 | 0.02 | 0.03 | 0.07 | | Other Assets | 2.65 | 4.57 | 9.5 | 23.32 | | Total Assets | 3.23 | 6.09 | 10.82 | 24.42 | ### Cash Flow All figures in ₹ crore unless the row name says otherwise. | Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | | --- | --- | --- | --- | --- | | Cash from Operating Activity | — | -0.55 | -1.39 | -3.83 | | Cash from Investing Activity | — | -1.1 | -0.23 | -0.06 | | Cash from Financing Activity | — | 1.84 | 1.44 | 5.27 | | Net Cash Flow | — | 0.19 | -0.18 | 1.38 | | Free Cash Flow | — | -1.63 | -1.6 | -3.9 | | CFO/OP | — | -40 | -46 | -46 | ### Ratios | Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | | --- | --- | --- | --- | --- | | Debtor Days | 169.15 | 39.21 | 98.03 | 89.77 | | Inventory Days | 735.53 | 112.03 | 96.55 | 142.67 | | Days Payable | 60.83 | 27.56 | 37.68 | 11.2 | | Cash Conversion Cycle | 843.84 | 123.68 | 156.9 | 221.24 | | Working Capital Days | 295.56 | 6.58 | 97.85 | 104.69 | | ROCE % | — | 22.61 | 39.18 | 52.15 | ## Shareholding Pattern ### Quarterly | Category | Mar 2026 | Sep 2026 | | --- | --- | --- | | Promoters | 95.14% | 68.13% | | FIIs | 0% | 7.54% | | DIIs | 0% | 0% | | Government | 0% | 0% | | Public | 0% | 14.68% | | Others | 4.86% | 9.65% | | No. of Shareholders | 42 | 42 | ## Technical Indicators Derived from daily closing prices and recomputed each trading session; values move with the market. - **Overall Signal:** Neutral - **Buy / Neutral / Sell:** 0 / 19 / 0 ### Moving Averages — summary: **Neutral** | Indicator | Value | Signal | | --- | --- | --- | | SMA (10) | — | Neutral | | EMA (10) | — | Neutral | | SMA (20) | — | Neutral | | EMA (20) | — | Neutral | | SMA (50) | — | Neutral | | EMA (50) | — | Neutral | | SMA (100) | — | Neutral | | EMA (100) | — | Neutral | | SMA (200) | — | Neutral | | EMA (200) | — | Neutral | ### Oscillators — summary: **Neutral** | Indicator | Value | Signal | | --- | --- | --- | | RSI (14) | — | Neutral | | MACD (12,26,9) | — | Neutral | | Stochastic (14,3,3) | — | Neutral | | ADX (14) | — | Neutral | | Williams %R (14) | — | Neutral | | ATR (14) | — | Neutral | | ROC (12) | — | Neutral | | Stoch RSI (14) | — | Neutral | | UO (7,14,28) | — | Neutral | ## Filings & Documents ### Earnings Call Documents | Date | Document | | --- | --- | | Oct 2026 | [Concall - Oct 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3b39f55-c275-4903-a3ef-5dc097ebe4f2.pdf) | ### Investor Presentations | Date | Document | | --- | --- | | 2026-10-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b3b39f55-c275-4903-a3ef-5dc097ebe4f2.pdf) | ### Exchange Filings & Announcements | Date | Document | | --- | --- | | 2026-10-04 | [Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Commercial Suit Filed Against The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1df655fe-b9c1-4708-b4c4-5455f952006c.pdf) | | 2026-10-03 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=217af02c-11e9-4655-b8c0-914734699178.pdf) | --- Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-10-13T11:01:22.547Z.